enda-dhea-trial-women-symptoms

name

enda-dhea-trial-women-symptoms

description

Suggests a trial of dehydroepiandrosterone (DHEA) replacement in women with primary adrenal insufficiency (PAI) who report low libido, depressive symptoms, and/or low energy levels despite otherwise optimized glucocorticoid and mineralocorticoid replacement. Consider when a woman with PAI presents with persistent low libido, depressive symptoms, and/or low energy levels after glucocorticoid and mineralocorticoid doses have been titrated to clinical targets.

Trial DHEA Replacement in Women with PAI and Specific Symptoms

STEP 1 — Gather Information

Confirm PAI diagnosis, review current glucocorticoid (e.g., hydrocortisone 15–25 mg/day) and mineralocorticoid (fludrocortisone 50–100 µg/day) doses, assess for clinical signs of over- or under-replacement (weight, BP, electrolytes), and document presence of low libido, depressive symptoms, and/or low energy levels.

STEP 2 — Rule In / Rule Out

Determine whether symptoms persist despite optimized steroid replacement; if yes, proceed to DHEA trial consideration, otherwise evaluate for other causes of fatigue or low libido (e.g., thyroid dysfunction, depression, anemia).

STEP 3 — Classify or Stratify

Classify the patient as a candidate for a DHEA replacement trial if she is a woman with PAI, has low libido, depressive symptoms, and/or low energy levels, and is on otherwise optimized glucocorticoid and mineralocorticoid therapy; proceed to step 4 to initiate the trial.

STEP 4 — Decide

Initiate a trial of DHEA 25–50 mg orally each morning, measure morning serum DHEAS before each dose aiming for the mid-normal range, and schedule clinical reassessment of libido, mood, and energy after 6 months; if sustained benefit is reported, continue therapy, otherwise discontinue DHEA.

Clinical Guardrails / Mimics / Pitfalls

Do not use DHEA as first-line therapy before optimizing glucocorticoid and mineralocorticoid replacement; avoid in men, pregnancy, or hormone-sensitive malignancies; monitor for androgenic side effects (acne, hirsutism, voice changes); do not rely solely on DHEAS levels without clinical response; DHEA is not routinely recommended due to insufficient evidence for broad use.

Concrete Clinical Example

A 48-year-old woman with autoimmune PAI on hydrocortisone 20 mg daily and fludrocortisone 100 µg daily reports persistent low libido and fatigue despite stable weight, normal BP, and normal electrolytes; after confirming optimized replacement, a trial of DHEA 25 mg each morning is started; at 6‑month follow‑up she notes improved energy and libido, DHEAS is mid‑normal, and therapy is continued.

Source: Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI:10.1210/jc.2015-1710